Migraine sufferers are about to get one more treatment option in the form of the new Zelrix Migraine Patch. The Zelrix Migraine Patch has recently been given the green light by the FDA to begin filing for a New Drug Application.
The Zelrix Migraine Patch was created by Pennsylvania-based NuPathe and uses a system called SmartRelief to administer medication. SmartRelief uses a tiny electrical current to move medication through the body in a process known as iontophoresis. All of this may sound a little confusing, but all it means is that a new non-oral migraine medication is on its way.
Key Themes Behind This Trend
- Non-oral Medication
- The trend towards non-oral medication for treating migraines presents an opportunity for disruptive innovation in drug delivery systems.
- Iontophoresis
- The trend towards using iontophoresis for drug delivery presents an opportunity for disruptive innovation in medical devices and technology.
- Migraine Treatments
- The trend towards new and innovative migraine treatments presents opportunities for disruptive innovation in the pharmacology industry.
Where This Applies
- Pharmacology
- The pharmacology industry can embrace the trend towards new and innovative migraine treatments by developing and marketing non-oral medication options such as the Zelrix Migraine Patch.
- Medical Devices
- The medical device industry can capitalize on the trend towards iontophoresis by manufacturing devices that can effectively deliver medication without the use of needles.
- Healthcare Technology
- The healthcare technology industry can explore the trend towards non-oral medication by developing new platforms and tools for delivering medication directly to patients, such as remote-controlled patches and wearable devices.
